IRLAB Therapeutics AB (publ)
IRLAB-A.ST - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$286.56M
Close$
$-0.45
121.4% downside
Current Fair Value
121.4% downsideOvervalued by 121.4% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $286.56 Million |
|---|---|
| Enterprise Value | $276.55 Million |
| Earnings per Share | $-1.64 |
| Beta | 0.56 |
| Outstanding Shares | 84,938,020 |
Return
| Return on Equity | -55.43% |
|---|---|
| Return on Assets | -29.52% |
| Return on Invested Capital | -46.03% |
Valuation & Multiples
| P/E Ratio | -2.97 |
|---|---|
| PEG | 7.33 |
| Price to Sales | - |
| Price to Book Ratio | 2.12 |
| Enterprise Value to Revenue | 3.49 |
| Enterprise Value to EBIT | -6.19 |
| Enterprise Value to Net Income | -6 |
| Total Debt to Enterprise | 0.09 |
| Debt to Equity | 0.25 |
Revenue Sources
No data
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$6.40 M
Consensus analyst estimateNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
$5.96 M
Consensus analyst estimateInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
About IRLAB Therapeutics AB (publ)
31 employees
CEO: Kristina Torfgard
IRLAB Therapeutics AB (publ) is a pharmaceutical company committed to developing treatments for Parkinson's disease. Its clinical pipeline features Mesdopetam, currently progressing through phase IIb/III studies to address dyskinesia, an...